Updated:
Immix Biopharma
Immix Biopharma, led by CEO Ilya Rachman, runs a dual-modality pipeline targeting CAR-T therapy for rare blood cancers and a biologic for solid tumors.
Immix Biopharma
Rachman founded Immix Biopharma in 2012, structuring the company as a clinical-stage biopharmaceutical developer with a pipeline weighted toward hematologic malignancies and solid tumors. The firm went public via a conventional IPO on Nasdaq in December 2021, raising $18 million to fund clinical trials. Unlike single-platform biotechnology startups, Immix built its portfolio around two therapeutic modalities — an autologous CAR-T cell therapy and a tissue-specific biologic — creating internal diversification across drug classes without relying on partner programs. Immix's most advanced program, NXC-201, is a BCMA-targeted CAR-T cell therapy being investigated in relapsed/refractory multiple myeloma and AL amyloidosis. The firm reported a 92% overall response rate in its optimized dosing cohort at the American Society of Hematology annual meeting in December 2022 (per the firm's official communications, 2022). In solid tumors, the company develops IMX-110, a tissue-specific biologic combining a chemotherapy payload with a poly-tyrosine kinase inhibitor, currently in Phase I/II trials for soft tissue sarcoma and colorectal cancer. The firm operates exclusively in the United States and Israel, where its discovery and manufacturing functions are based. Immix runs lean as a clinical-stage biotech, disclosing fewer than 30 full-time employees and relying on contract manufacturing organizations for CAR-T vector production. In September 2023, the firm secured a $30 million private placement from institutional investors, extending cash runway into 2025 (per the firm, September 2023). The company also formed a subsidiary, Immix Biotherapeutics, which in 2023 began enrolling patients in Italy and the Netherlands for NXC-201's European clinical expansion. Immix stands apart structurally by running parallel CAR-T and biologic programs under a single corporate roof at a stage where most peers remain single-asset. The CAR-T program targets a well-validated antigen through a construct designed for improved persistence, while the biologic arm uses a dual-warhead mechanism to address tumor heterogeneity — a pairing that gives the firm two shots at an inflection point without subsidiary spinoffs or royalty-heavy licensing structures typical of biotechs its size.
General information
Firm type
Asset Manager
Year founded
2012
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Los Angeles
Corporate office
Los Angeles, CA, United States
Principals
Ilya Rachman
Chief Executive Officer
Gabriel Morris
Chief Financial Officer
Sector focus
Frequently asked questions
Who leads Immix Biopharma's clinical and corporate strategy?
Ilya Rachman serves as CEO and chairman. He founded the firm in 2012 and has overseen the pipeline from preclinical through Phase II trials. Gabriel Morris serves as CFO, managing the firm's capital raises including the 2021 IPO and a 2023 private placement.
How does Immix Biopharma's two-program structure differ from its biotech peers?
Immix runs a CAR-T cell therapy (NXC-201) and a tissue-specific biologic (IMX-110) internally. Most clinical-stage biotechs Immix's size advance a single lead candidate. The dual-modality approach spreads development risk across two distinct drug classes and two oncology segments — hematologic and solid tumors — without relying on partnered programs.
What indications does NXC-201 currently target?
NXC-201 is a BCMA-targeted autologous CAR-T being studied in relapsed/refractory multiple myeloma and AL amyloidosis. At the December 2022 American Society of Hematology meeting, Immix reported a 92% overall response rate in its optimal dosing cohort. The firm has expanded European enrollment for NXC-201 into Italy and the Netherlands.
Is Immix Biopharma public, and when did it list?
Yes. Immix Biopharma trades on Nasdaq under the ticker IMMX after completing a conventional IPO in December 2021, which raised approximately $18 million. The firm has since augmented its balance sheet with a $30 million private placement closed in September 2023.
What is Immix Biopharma's operational footprint?
The firm is headquartered in Los Angeles, California, and conducts discovery and manufacturing functions in Israel. Clinical operations for NXC-201 extend into Europe, with active trial sites in Italy and the Netherlands. Immix relies on contract manufacturing organizations for vector production rather than building internal capacity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: